GMAB Genmab - ADR

Between $GMAB, $ZYME, $CORT ( $IMGN/ $ABBV not to be forgotten as well for paving the way), the list goes on Crazy amount of competition in the ovarian cancer space (but exciting time for patients!)

I told you for Genmab you don’t listen now the train leave the station… Next time listen… $GMAB $INCY but don’t miss the run for Ascendis big catalyst coming $ASND $IBB $XBI

$GMAB Encouraging Phase 2 petosemtamab data in colorectal cancer: 75% ORR in first line and 67% in second line, including confirmed and unconfirmed responses, combined with chemotherapy. Still needs randomized Phase 3 confirmation, but promising potential beyond head and neck cancer. Long-term bullish!! 📈

$GMAB Look at the big money options flow you fool. Your posts on this board are nothing to the big money.

$GMAB nothing wrong with a very small dip after only climbing, the candles are very bullish. Lets reach 60 and beyond 👅

$GMAB Growing royalties, positive Phase 3 EPKINLY data and promising Rina-S results. Plenty of pipeline upside backed by an already profitable business. Added a few more. Bullish on the long-term story 😎

$GMAB from low 20’s I watched and watched and watched. I was the ultimate pus&sy surveyor here and deserve to not participate. Congrats to all who had fortitude on this obscure minuscule volume boredom. Those are the signs of a 💎

$GMAB this will come back down. They are going to lose the royalties on their other drug soon.

$GMAB $KOD $SLS Appreciate the shoutout! Flagged $GMAB yesterday, 2 of the 3 names in that post have now delivered major news. Still watching $SLS closely for the 80th event and Phase 3 readout. Sharing my biotech watchlist and catalyst research here..

$GMAB I tried to warn the shorts this morning they had no idea what was happening. Congrats longs.

$GMAB +29.8% to 57.96, gapped from 44.64 and ran to 58.54. Blew through the 45.44 Oct 26 high, now miles over the 20-day (39.46). Hold 54 and 58.54 gets tested again 🔥

$GMAB Are you insane? Do you even know what is happening??? Check the options flow fool before you lose big $$$. Idiot shorts see a stock up but do not real DD.

$GMAB ugh just seeing this. favve this to us via his SA. Those tips have been money! I’m just gonna start buying all the undervalued names in that list. Fook me

Genmab Monday is what a real readout looks like imo $GMAB up about 13 percent in Europe this morning Rina S cut the risk of death 57 percent in advanced ovarian cancer and cut progression risk 71 percent versus chemo first late stage results for the drug, not a teaser colorectal follow up on petosemtamab pointed the same way over the weekend that is a pipeline stacking wins, not hoping for one

$GMAB busy this weekend, 2 headline one this morning and another yesterday. Large options flows here too on Friday. Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer ""Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients"

$GMAB Phase 3 RAINFOL-02 readout landed Friday, and the numbers are pretty clean. Rina-S cut the risk of progression or death 71% vs investigator-choice chemo in platinum-resistant ovarian cancer (hazard ratio 0.29, p<0.0001), and overall survival showed a 57% risk reduction (HR 0.43). That was in 584 patients regardless of FRa expression or prior mirvetuximab, which is what the Phase 2 data earlier this month could not prove on its own. No new safety signals either. Full data goes to a future medical meeting, and Genmab is taking it to regulators. Investor update is Oct 28.

$GMAB Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice chemotherapy Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC) Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide

$GMAB 🏥 Genmab A/S announced positive topline results from the Phase 3 RAINFOL-02 trial showing rinatabart sesutecan met the primary progression-free survival endpoint and key secondary overall survival endpoint with statistically significant and clinically meaningful improvement versus investigator's choice chemotherapy in platinum-resistant ovarian cancer. Selected from hundreds of headlines

35 days out and $GMAB has a date worth watching Dec 14 at ASH, first Phase 3 readout for EPCORE DLBCL-4, epcoritamab plus lenalidomide in relapsed DLBCL. ASH put it in the press program, they do not spotlight the boring ones 22 epcoritamab abstracts total, 6 orals, plus a full R&D update Dec 16 stock is holding around 55 today, up about 2.5% and miles above its 50 day near 39 it started the year near 31

📊🔥 Top Gainers Update 💰🚨 RTH 3:33pm ET Focusing on movers with the strongest fresh catalysts: $GMAB +28.87% – Major Phase 3 win: LiGeR-HN1 met both primary endpoints, with petosemtamab + Keytruda cutting death risk by 50% versus Keytruda alone. $AXGN +31.55% – Q3 revenue rose 26.2% to $75.8M, adjusted EPS beat estimates, and FY2026 revenue guidance was raised to at least $290M. $BOOM +38.88% – Strong Q3: sales rose 14% to $172.8M, adjusted EBITDA improved sharply, and free cash flow reached $16.6M. $KIDS +30.92% – Record Q3 revenue of $72.7M, up 19% YoY, with 2026 guidance increased. $LUNG +30.56% – Q3 revenue reached $22.8M, while net loss fell 40% and adjusted EBITDA loss improved 57% YoY.